Pharmaceutical companies have accelerated the process of commercialization and enhanced the ability of "hematopoietic"

 In recent years, with the continuous and rapid development of China's innovative drug industry, some commercialized varieties have the potential to be blockbuster varieties.
The industry said that pharmaceutical companies have the opportunity to achieve greater success in the commercialization stage by adopting innovative drug strategies that are in line with their own resource endowments
.
Nowadays, more and more pharmaceutical companies have begun to accelerate the commercialization of products to enhance their own "hematopoietic" ability
.
Recently, some pharmaceutical companies have expressed that they will accelerate the commercialization process
.
Recently, TOT BIOPHARM released its 2021 performance report, showing that in 2021, the company's operating income increased by 239.
36% year-on-year to RMB 76.
325 million
.
The company has 3 products that have obtained the marketing authorization of the State Drug Administration
.
The announcement also pointed out that at the same time as the new drug was launched, TOT BIOPHARM and domestic pharmaceutical companies carried out strategic cooperation in market promotion, promoted the process of product commercialization, and improved the availability of drugs
.
It is reported that TOT has successively cooperated with Jiangxi Jixin Pharmaceutical Co.
, Ltd.
(a subsidiary of Jimin Trusted Group) on the promotion of Puxinting and Tizhian in the Chinese market, and has also cooperated with Kexing Biopharmaceutical Co.
, Ltd.
on the commercialization of Puxinting in overseas markets.
Licensing reached a strategic cooperation to further enhance TOT BIOPHARM's market influence in domestic and overseas markets; and reached a marketing promotion of Mesiah in the field of AIDS with Biopharmaceuticals (Nanjing) Co.
, Ltd.
, and actively contributed to the treatment of AIDS cachexia
.
In addition to TOT BIOPHARM, the new journey of commercialization of Ascentage Pharmaceuticals has also been fully launched
.
The company has formed a commercialization team with rich experience in the field of hematology and tumor, and has cooperated in depth with Innovent to jointly promote the commercialization of Nerica in China
.
In 2021, Ascentage Pharma is actively deploying, and has established strategic partnerships with supply chain service providers represented by Sinopharm Holding, Shanghai Pharma Holdings and China Resources Pharma, to promote the commercialization process and accessibility of Nerlik in multiple dimensions
.
It is reported that the core product of Ascentage Pharma, the third-generation BCR-ABL inhibitor orabatinib (trade name: Nerlik) has been officially approved for marketing in China, which marks the company's transformation from a research and development-oriented enterprise to a product launch.
Enterprises with commercialization capabilities successfully leapfrog and start a new journey of commercialization in an all-round way
.
Data shows that in 2021, Ascentage Pharma’s revenue will increase by 123.
2% year-on-year to 27.
91 million yuan, mainly from the sales of the first commercialized product, commercialization license fee income and intellectual property license fee income
.
Hua Medicine also announced in its 2021 annual report that the company has made every effort to promote the commercialization of dopagliflozin
.
In the process of commercialization of Dopagliflozin, Hua Medicine has made full arrangements and preparations in logistics and warehousing, supply chain management, channel informatization, and market promotion
.
The company said that in the future, Hua Medicine will continue to strengthen its cooperation with Bayer, and join hands with production and supply chain partners such as WuXi AppTec, Sinopharm, Desano, and Ribo Pharmaceuticals to jointly promote the stable production of dopagliflozin.
, adequate supply and marketing
.
If approved, Hualing will work with its partner Bayer to promote the commercialization of dopagliflozin in China, and strive to enter the national medical insurance list to expand dopagliflozin for monotherapy or in combination with other existing hypoglycemic drugs Prospects of combination therapy for the treatment of type 2 diabetes mellitus
.
In addition, Beihai Kangcheng said that it plans to expand its internal full-time commercial team, and it is expected to form a mature rare disease commercialization team with more than 300 members in China in the next five years
.
Among them, Hunterase, as the first commercial rare disease product of Beihai Kangcheng, was approved for marketing in China in September 2022 for the treatment of mucopolysaccharidosis type II (MPS II or Hunter syndrome)
.
Analysts said that China's innovative drug industry has entered a stage of mature commercialization competition.
For example, biotech companies that have entered the market are striving to achieve transformation through successful commercialized products, and big pharma/biopharma, which has commercial varieties, has cultivated a certain scale of sales and marketing teams.

.
And those companies with certain commercialization capabilities, reasonable layout of pipelines under development, good clinical trial results, and companies whose number is in line with the company's R&D capabilities and capital level have higher investment value
.
It is reported that the relevant person in charge of Henlius recently stated that the company will evolve from a Biotech (biotechnology) company to a Biopharma (biopharmaceutical) company in 2022
.
At the same time, it believes that one of the criteria for a Biopharma company is, "financially able to rely on cash flow from product sales, get rid of dependence on external funds, and form a healthy operating state
.
" Disclaimer: In any case, the information in this article The opinions expressed or expressed do not constitute investment advice to anyone
.